CSIMarket
 
Lucid Diagnostics Inc   (NASDAQ: LUCD)
Other Ticker:  
 
 
Price: $0.9497 $0.02 2.118%
Day's High: $0.9498 Week Perf: 2.79 %
Day's Low: $ 0.91 30 Day Perf: 15.82 %
Volume (M): 332 52 Wk High: $ 1.40
Volume (M$): $ 315 52 Wk Avg: $0.90
Open: $0.93 52 Wk Low: $0.63



 Market Capitalization (Millions $) 48
 Shares Outstanding (Millions) 50
 Employees 109
 Revenues (TTM) (Millions $) 4
 Net Income (TTM) (Millions $) -45
 Cash Flow (TTM) (Millions $) -10
 Capital Exp. (TTM) (Millions $) 0

Lucid Diagnostics Inc
Lucid Diagnostics Inc is a medical technology company that specializes in developing non-invasive diagnostic solutions for various diseases. The company focuses on the field of gastrointestinal diseases and provides a range of innovative products and services to help improve patient outcomes. They aim to revolutionize the diagnosis and treatment of gastrointestinal disorders by utilizing advanced imaging and data analytics techniques. Lucid Diagnostics Inc is dedicated to providing accurate and efficient diagnostic tools that can be easily integrated into clinical practice, ultimately leading to better patient care and management.


   Company Address: 360 Madison Avenue New York 10017 NY
   Company Phone Number: 813-1828   Stock Exchange / Ticker: NASDAQ LUCD


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
BAX   -4.91%    
BDX   -7.92%    
BSX        2.66% 
EW   -1.53%    
IART        0.8% 
MDT        0.18% 
• View Complete Report
   



Lucid Diagnostics Inc

Lucid Diagnostics Inc Faces Financial Struggles Despite Surge in Revenue

In the fast-paced and ever-changing world of the stock market, it's important to keep a close eye on the performance of various companies. One such company that has recently caught the attention of investors is Lucid Diagnostics Inc (LUCD). With its impressive revenue improvement and positive industry comparisons, LUCD has positioned itself as a promising prospect for potential investors.
In the first quarter of 2024, LUCD reported a remarkable revenue improvement of 124.439% year on year, bringing in a substantial $1.00 million. This growth is even more significant considering that the Medical Equipment & Supplies sector, on average, only experienced a 7.26% business improvement during the same period. LUCD's performance is a testament to its strong market position and ability to outperform its competitors.

Lucid Diagnostics Inc

Lucid Diagnostics Inc's Financial Report Reveals Positive Trends in Fourth Quarter of 2023



Lucid Diagnostics Inc has recently released its financial report for the October to December 31, 2023 period, showcasing some encouraging trends. With decreased losses per share, a surge in revenue, and improved income per share, Lucid Diagnostics Inc's performance in the stock market is gaining attention. In this article, we will highlight some interesting facts from the financial report and delve into the significance of these numbers.
Decreased Losses Per Share:
Lucid Diagnostics Inc's financial report indicates a significant improvement in its losses per share. Compared to $-0.40 per share reported a year ago, the company has successfully reduced its losses to $-0.23 per share, representing a decrease of 42%. This reduction is a positive sign for investors and indicates potential profitability in the future. Furthermore, Lucid Diagnostics Inc's losses per share have decreased from $-0.34 in the preceding financial reporting period to $-0.23, showcasing a consistent trend of improvement.







Lucid Diagnostics Inc's Segments





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com